Wrapmanager Inc. Has $303,000 Holdings in Glaukos Corp (NYSE:GKOS)

Wrapmanager Inc. cut its position in Glaukos Corp (NYSE:GKOS) by 14.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,018 shares of the medical instruments supplier’s stock after selling 690 shares during the period. Wrapmanager Inc.’s holdings in Glaukos were worth $303,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in GKOS. Amundi Pioneer Asset Management Inc. boosted its position in Glaukos by 136.7% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 178,502 shares of the medical instruments supplier’s stock valued at $13,989,000 after buying an additional 103,102 shares in the last quarter. State of Wisconsin Investment Board boosted its position in Glaukos by 29.7% in the first quarter. State of Wisconsin Investment Board now owns 222,400 shares of the medical instruments supplier’s stock valued at $17,429,000 after buying an additional 50,900 shares in the last quarter. Norges Bank acquired a new position in Glaukos in the fourth quarter valued at about $2,803,000. Geode Capital Management LLC lifted its position in shares of Glaukos by 14.0% during the fourth quarter. Geode Capital Management LLC now owns 365,226 shares of the medical instruments supplier’s stock worth $20,513,000 after purchasing an additional 44,867 shares in the last quarter. Finally, Granite Investment Partners LLC lifted its position in shares of Glaukos by 16.0% during the first quarter. Granite Investment Partners LLC now owns 293,672 shares of the medical instruments supplier’s stock worth $23,015,000 after purchasing an additional 40,555 shares in the last quarter. Hedge funds and other institutional investors own 96.59% of the company’s stock.

Shares of GKOS stock opened at $60.52 on Thursday. Glaukos Corp has a 1 year low of $39.05 and a 1 year high of $84.65. The business’s 50 day moving average is $74.95. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -163.57 and a beta of 1.61. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.72 and a quick ratio of 6.23.



Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, August 7th. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.03). Glaukos had a negative return on equity of 5.88% and a negative net margin of 5.93%. The company had revenue of $58.60 million for the quarter, compared to analyst estimates of $56.24 million. During the same quarter in the previous year, the company posted ($0.15) earnings per share. Glaukos’s revenue for the quarter was up 35.8% on a year-over-year basis. Equities research analysts anticipate that Glaukos Corp will post -0.39 earnings per share for the current year.

A number of equities analysts have recently issued reports on the stock. BTIG Research reiterated a “hold” rating on shares of Glaukos in a research report on Sunday. Zacks Investment Research upgraded shares of Glaukos from a “hold” rating to a “strong-buy” rating and set a $82.00 target price on the stock in a research report on Tuesday, April 30th. Finally, BMO Capital Markets upped their target price on shares of Glaukos from $66.00 to $71.00 and gave the stock a “market perform” rating in a research report on Thursday, May 9th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. Glaukos presently has a consensus rating of “Buy” and a consensus target price of $72.56.

In related news, CFO Joseph E. Gilliam sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $73.25, for a total transaction of $183,125.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 21,596 shares of company stock worth $1,612,742 over the last quarter. 8.70% of the stock is owned by company insiders.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.

Featured Story: What are Bollinger Bands?

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.